We examined human tonsillar B cells for expression of autoantibody heavy-chain or kappa light-chain cross-reactive idiotypes (CRIs), respectively defined by murine MAbs G6 or 17.109. We find 17.109 or G6 each specifically binds a subpopulation of B cells, respectively reacting with 3.8±3% (mean±SD) or 2.0±1.2% of all tonsillar lymphocytes. Cells reactive with both 17.109 and G6 comprise only 0.4±0.3% of tonsillar lymphocytes. Although each tested specimen had 17.109-positive cells, 2 of 19 tonsils (11%) did not have any G6-reactive cells. We find that CRI-positive cells and CD5 B cells both co-express slgD but fail to bind peanut agglutinin or MAbs specific for CD10, indicating that both cell types reside in the mantle zones of secondary B cell follicles. However, less than half of the B cells bearing one or both of these CRIs express detectable levels of CD5. Nevertheless, we find that G6-reactive lymphocytes constitute a multiclonal population of cells that express homologous heavy chain variable region genes, each rearranged to one of several distinct and apparently nonmutated D and JH gene segments. Collectively, these studies indicate that expression of nondiversified autoantibody-encoding variable region genes may not be an exclusive property of B cells that bear detectable levels ofthe CD5 surface antigen. (J. Clin.
Introduction
Malignant B cells from patients with chronic lymphocytic leukemia (CLL)' or small lymphocytic lymphoma (SLL) frequently express antibodies bearing cross-reactive idiotypes (CRIs) associated with IgM autoantibodies. In a study of over 30 CLL patients, one-fourth of the patients with kappa light chain-expressing leukemia cells had malignant lymphocytes that expressed a CRI defined by reactivity with a MAb, designated 17.109 (1) . This antibody, prepared against an IgM rheu-matoid factor (RF) recognizes a kappa light chain-associated CRI present on many IgM paraproteins with RF activity (2, 3) . Furthermore, nearly one-fifth of all surface Ig-expressing CLL were found to react with G6 (4). This MAb is specific for an Ig heavy chain-associated CRI present on several RF paraproteins (5) . Interestingly, nearly halfofthe CLL cases with leukemia cells reactive with 17.109 also reacted with G6, reflecting a biased co-expression of these CRIs (4, 6) .
Evaluation of the molecular basis for these CRIs in CLL revealed that each is a serologic marker for expression of a conserved immunoglobulin V gene(s) with little or no somatic mutation. The 17.109-reactive neoplastic B cells from unrelated patients express nearly identical kappa light chain variable region genes (VK genes) that belong to the VKIIIb sub-subgroup (7, 8) . Finally, the sequences of the VK genes expressed by 17.109-reactive leukemia cells share > 99% nucleic acid sequence homology with a germline VKIII gene isolated from placental DNA, designated Humkv325 (9) . Similarly, G6-reactive leukemia cells from unrelated patients express homologous heavy chain variable region genes (VH genes) of the VH1 subgroup (10) . Moreover, comparisons of the deduced amino acid sequences of G6-reactive CLL and that of G6-negative antibody heavy chains encoded by VH 1 genes suggest that the G6-CRI in CLL is relatively resilient to substitutions within complementarity determining region 3 (CDR3), but affected by permutations within CDR1 and CDR2. Together these data argue that the G6-CRI in CLL is a serologic marker for a conserved VH 1 gene also expressed with little or no somatic mutation.
Conceivably, the frequent expression of these autoantibody-associated CRIs in CLL or SLL may reflect the repertoire ofthe presumed normal cell counterpart to these malignancies, namely the cluster of differentiation antigen 5 (CD5) B cell. CD5 B cells constitute a small subpopulation ofhuman B lymphocytes in lymphoid organs and peripheral blood of normal adults ( 1-1 5) . These cells comprise the majority of B cells in the primary follicles of human fetal spleen (16, 17) , where high proportions of cells express these CRIs (18) . Finally, CD5 B lymphocytes have been reported to include nearly all the cells that spontaneously produce IgM autoantibodies (19, 20) , including RF. As noted, IgM autoantibodies frequently bear the 17.109 CRI or the G6 CRI (3, 5, 21) . Also, IgM molecules co-expressing both CRIs almost invariably have RF activity (22) . However, the relationship between CD5 B cells and nonmalignant B cells that co-express autoantibody-associated CRIs has not been evaluated. Accordingly, we examined human tonsillar lymphocytes to determine the prevalence and surface antigen phenotype of the B cells that bear the 17 (7, 10) . Plasmid DNA containing amplified recombinant insert DNA was isolated for double-stranded DNA sequencing as described (32) . In addition, 1/20th of the PCR reaction mixture was analyzed by the method of Southern, as described (8) .
Oligonucleotide probes corresponding to the anti-sense of a sequence in the second complementarity determining region (G6-CDR2) [dGCGTAGTTTGCTGTACC] or to the anti-sense of a sequence in the second framework region (VHI-FR2) [dCCATCCACT-CAAGCCCJ of the VHI gene expressed by G6-reactive CLL (10) were used to probe the filter-immobilized DNA. Oligonucleotide synthesis, labeling, hybridization, and washing conditions were as described (1) 
Results
Multiparameter flow cytometric analyses oftonsillar lymphocytes. We examined the lymphocytes from 19 tonsils using multiparameter flow cytometric analyses. Although most specimens were from young adults with acute or chronic tonsillitis, two surgical specimens (nos. 8 and 16 in Table I ) were from patients with obstructive sleep apnea that required tonsillectomy to ameliorate partial upper airway obstruction. We could not discern any consistent phenotypic difference between these two and the other lymphocyte populations (Table I ). The proportion ofCD I 9-positive B cells (73±16%; mean±standard deviation) generally exceeded the proportion of CD3-positive T cells (23±14%) by twofold (Table I) .
We readily detected CD5 B cells in each tonsil specimen ( Table I) (15) , the proportions of tonsillar lymphocytes that co-expressed CD5 and pan-B lymphocyte surface antigens ranged from 2% to 36% of the total lymphocytes or from 3% to 42% of the total B cells (Table I) .
We examined tonsillar lymphocytes for reactivity with 17.109 or G6. With few exceptions, each tonsil contained a subpopulation of CRI-positive B cells that expressed the 17.109 and/or the G6 CRI (Table I) (Table I ). In contrast, specimen no. 18 had a much greater proportion ofCD5 B cells (36%) than tonsil no. 3, but still had proportions ofCRI-bearing cells that were comparable to that of specimen no. 3 (Table I) . Secondly, over one halfof the tonsillar B cells expressing 17.109 and/or G6 do not express detectable levels ofthe CD5 surface antigen. For example, cells staining with PE-17.109 display brighter green fluorescence when co-stained with FITC-anti-CD5 than with FITCanti-CD3 (Fig. 2) . However, a large fraction of the anti-CD5 stained CRI-positive cells (dashed line, Fig. 3 (10) . The heterogeneity noted in the fifth base ofeach sequence reflects the sequence of the VH1 primer used to amplify the rearranged VH genes (Fig. 4) . This primer has an A/C/T wobble at this position. Except for clone L8, all clones contain functionally rearranged VHl genes. The VH gene of L8 is an apparent pseudogene. This VH gene has a single point deletion in the second base of codon 71 (Fig. 4) that produces downstream termination codons in the third framework and complementarity determining region (Figs. 4 and 5 ). All other clones have functional VH1 genes without stop codons or gene rearrangements that shift the reading frame of downstream gene segments. Despite each clone having nearly identical VH regions, there is great diversity among the various clones in the third CDR (CDR3) and fourth framework regions. These regions are encoded by the D and JH gene segments, that undergo recombination and amino-terminal nucleic acid base insertion immediately before VH gene rearrangement (42, 43) . As such, the sequence ofthe CDR3 generally is idiosyncratic to each Ig V gene rearrangement. Only two clones, L17 and L37, share identity in the deduced CDR3 region, indicating that these two variable region genes most likely were derived from the same B cell clone (Fig. 5) . All other clones have highly distinctive sequences in the deduced CDR3 region, indicating that each was derived from an independent Ig V gene rearrangement (Fig. 5) . Most clones have a segment within CDR3 that has a high degree ofsequence homology with a known germline D minigene (37) (38) (39) (40) (41) (Fig. 5) . Of the 14 distinct clones analyzed, at least 11 different germline D segments may be represented. In the region presumably encoded by a rearranged JH gene segment, nearly half (6/13) of the 13 distinct and apparently functional clones use JH4 (L17/37, L25, L34, L36, L39, and L41), three 17 .109/G6+ Cells Alternatively, CRI-bearing B lymphocytes may constitute a B cell population with characteristics of the CD5 B cell. Although used as a marker for a subpopulation ofB lymphocytes, the expression ofCD5 has no known relationship to the apparent physiology ofthe CD5 B cell, and may in fact be an epiphenomenon (reviewed in reference 45). Furthermore, B cells cannot be delineated readily into discrete subpopulations based on the detectable level of CD5 surface antigen. Enumeration of CD5 B cells requires subtraction methods, in which the percent number of isotype-control-stained B cells that have fluorescence above a certain threshold is subtracted from percent number ofanti-CD5-MAb-stained cells that are detected above that same threshold. Cells with extremely low levels of CD5 may not fluoresce brightly enough to be scored as positive, even when stained with the brightest of fluorochrome-labeled anti-CD5 MAbs. As such, it may be argued that all CRI-bearing B cells actually may express CD5, but at levels below detection using flow cytometric analyses.
Finally, CRI-bearing "CD5-negative" B cells may be similar to the CD5-negative "sister" population of B cells detected in the mouse (46) (47) (48) . In experiments aimed at characterizing the CD5 B cell population and its progenitors in the mouse peritoneum, peritoneal B cells were found that did not express surface CD5 but apparently had other phenotypic traits peculiar to CD5 B cells (46) , such as the surface expression ofMAC-1 (CDl lb) (49), extended longevity in vitro, or ability to generate spontaneous oligoclonal B cell expansions in vivo that resemble human B cell CLL (50) . In transfer experiments, such CD5-negative sister cells initially were found to reconstitute mice only whenever the adoptive hosts were reconstituted with CD5 B cells (46) . More recent studies, however, suggest that such cells may constitute a related but possibly independent and self-renewing B cell subpopulation that may arise latter in ontogeny than B cells that express detectable levels ofthe CD5 surface antigen (46, 48) . By analogy, CD5-negative CRI-bearing B cells may be generated at a later stage of B cell development than CRI-bearing CD5 B cells, but still express many of the traits that are associated with the CD5 B cell.
One peculiar phenotypic characteristic proposed for CD5 B cells is stable Ig V gene expression with little or no somatic mutation. Independent clones of CD5 B cells may express identical V genes without evidence for somatic mutation (51, 52) . The antibodies encoded by such V genes frequently are reactive with a variety of self antigens, i.e., proteolytically processed erythrocyte membranes, denatured DNA, and/or the Fc portion of self IgG (53) (54) (55) (56) (57) . Stable expression of such V genes with little or no somatic mutation may account for the finding that CD5 B cells are enriched for cells that spontaneously produce IgM autoantibodies (19, 20) .
In this light, it was important to examine the V genes expressed by CRI-bearing cells. Previous studies indicated that the G6 CRI was found on Ig heavy chains ofthe VH1 subgroup (58) . In CLL, G6 reactive leukemia cells were found to express identical VH 1 genes, indicating that the G6 CRI is a marker for one VH1 gene(s) expressed with little or no somatic mutation (10). However, it was not known whether this relationship is valid for nonmalignant G6-reactive B cells. Conceivably, B cells free to permute their expressed V genes through the process of somatic mutation may express G6-reactive Ig encoded by other VHl genes or VHl genes that have diversified from those present in the germline DNA. Indeed, the VHl heavy chains of a few IgM autoantibodies that share only modest homology to the heavy chain expressed by G6-reactive CLL are known to react with the G6 MAb (58) . Particularly in light of the finding that a large fraction of G6-reactive cells do not express detectable levels of CD5, it was important to examine the VH 1 genes used by cells expressing the G6-CRI.
Nucleic acid sequence analyses of the Ig VH1 genes rearranged and presumably expressed in G6-reactive cells revealed little evidence for somatic mutation. Other than clones LI 7, L30, and L34, all other clones have VHl genes that were identical to L7 (Fig. 4) . The VH genes of clones LI 7 and L34, that apparently are derived from the same B cell clone (LI 7/ L34), differ from L7 at only two sites (Fig. 4) . LI 7 and L34, moreover, share with an independent clone, L30, the same nonconservative G -> A substitution in codon 74. Conceivably the L17/L34 and the L30 VHl genes are derived from the same allele. In this case, the common base substitution noted in these clones may represent an allelic polymorphism in the VH1 gene(s) encoding G6-reactive heavy chains, rather than a somatic mutation event. In any case, in over 5,600 bases evaluated for the VH genes of the 13 independent and functional clones, we find only three base substitutions, representing a fidelity in the DNA sequences of > 99.94%. The absence of even nonconservative base changes indicates that the conserved VH gene sequences are not the mere consequence of selection for cells having reactivity for the G6 MAb. Rather, these data indicate that G6-reactive tonsillar B cells express homologous VH1 genes with little or no somatic mutations.
Even in the CDR3 region, much ofthe diversity apparently is not the result of somatic mutation subsequent to Ig gene rearrangement. Except at sites flanking the D region that may be generated by amino-terminal sequence insertions, threefourths of the independent clones (1 1/15) have short stretches of complete homology with known germline D segments (L7, L8, L22, L24, L26, L30, L33, L34, L36, L39, L42). Also, except for codons immediately contiguous to the D-JH junction, all clones that use the same JH gene segment have sequences TyrTyrTyrTyrTyrGlyMetAspValTrpGlyGlnGlyThrThrValThrValSerSer TACTACTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA that differ from known germline JH gene segments at the same site and with the same base substitution (Fig. 5) . For example, all clones with JH4 differ from published germline JH4 minigenes (59) with a A --G substitution in the sixth codon of the JH segment (Fig. 5 ). In addition, an A -G substitution at this same location was noted in the deduced JH4 gene segment used by G6-reactive leukemic cells (10) It is unlikely that the methods used in this study skewed our analyses to favor isolation of rearranged V genes that not undergone somatic mutation. We used primers corresponding to consensus sequences common to all JH gene segments and to a sequence at the 5' region of all VH 1 leader sequences. Conceiv-2094 ably, chance mutations in a rearranged VH1 gene at the sites recognized by these primers may disrupt the ability ofthat VH l gene to be amplified by our methods. However, these same primers have successfully amplified VHl genes other than those found in this study, including VHl genes that have undergone apparent somatic mutation subsequent to V gene rearrangement. (T.J. Kipps, R. Kobayashi, and S. Duffy, unpublished observations). Also, the amount ofVHl gene product produced in PCR of G6-reactive tonsillar lymphocytes is comparable to that produced in PCR of G6-reactive leukemia cell DNA. Thus, it seems unlikely that the bias introduced by our methods could account for the results that we obtained in this study. Rather, a more likely explanation is that G6-reactive tonsillar B cells express homologous VH 1 genes with little or no somatic mutations.
Consistent with this interpretation is our finding that some of the tonsils tested did not have any cells reactive with G6. If the G6 MAb could bind to heavy chains encoded by several different VH I genes, then finding persons without any G6-positive cells would be unlikely. That over I10% ofthe tonsils examined did not have any cells reactive with the G6 MAb, indicates that a fairly high proportion ofthe population may lack expression of any VH genes that can encode Ig heavy chains with this major CRI. Considering the conservation noted in the VHl gene sequences of G6-reactive cells ( [10] and this study), the frequent expression of the VH 1 gene(s) encoding the G6-CRI the fetal immune repertoire (18, 60) , the association of the G6-CRI with IgM autoantibodies (5, 61) , and relative high-frequency expression of this CRI in CLL and SLL (4, 6) , the absence of G6 expression may reflect a polymorphism in VH 1 gene use that possibly has physiologic significance.
Finally, these studies indicate that a relatively high proportion of mantel zone lymphocytes expresses autoantibody-associated CRIs. sIgD-bearing cells constitute only a fraction ofthe total B cells, ranging from 37% to 87% of the CD19-positive cells (Table I) . As noted, the 17.109 CRI and/or the G6 CRI predominantly is expressed by cells that co-express sIgD. Since such sIgD bearing cells predominantly represent mantle zone lymphocytes, the 17. 109-reactive, or G6-reactive cells, respectively, may constitute 4-17% and 0-12% of the mantle zone lymphocytes. These frequencies approach those noted for CRI expression in CLL. Conceivably transformation of lymphocytes such as those found in the mantel zone may account for the high frequency expression ofautoantibody-associated CRIs in CLL and related malignancies. However, there is an apparent bias for co-expression of both 17.109 and G6 by leukemia cell populations that is not noted in most tonsillar lymphocyte populations studied. Biased co-expression of the 17.109 CRI and the G6 CRI by leukemia cell populations may reflect selection of CRI-bearing cells based upon the binding activities of the expressed Ig. Further comparative analyses ofthe immunoglobulins produced by malignant and normal B cells may help resolve whether neoplastic CRI-bearing cells arise from a subset of normal CRI-bearing B lymphocytes.
